The estimated Net Worth of J Mervyn Nabors is at least $7.71 Milion dollars as of 3 June 2004. J Nabors owns over 1,096,572 units of AIM ImmunoTech Inc stock worth over $3,800 and over the last 20 years J sold AIM stock worth over $7,708,901.
J has made over 1 trades of the AIM ImmunoTech Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently J sold 1,096,572 units of AIM stock worth $7,708,901 on 3 June 2004.
The largest trade J's ever made was selling 1,096,572 units of AIM ImmunoTech Inc stock on 3 June 2004 worth over $7,708,901. On average, J trades about 1,096,572 units every 0 days since 2004. As of 3 June 2004 J still owns at least 12,262 units of AIM ImmunoTech Inc stock.
You can see the complete history of J Nabors stock trades at the bottom of the page.
J's mailing address filed with the SEC is 271 BAYSIDE DR, , CLEARWATER BEACH, FL, 34630.
Over the last 20 years, insiders at AIM ImmunoTech Inc have traded over $15,026,013 worth of AIM ImmunoTech Inc stock and bought 898,126 units worth $656,210 . The most active insiders traders include Thomas K Equels, J Mervyn Nabors oraz Commercial Bank First. On average, AIM ImmunoTech Inc executives and independent directors trade stock every 125 days with the average trade being worth of $16,943. The most recent stock trade was executed by Thomas K Equels on 6 May 2024, trading 61,729 units of AIM stock currently worth $25,309.
aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as
AIM ImmunoTech Inc executives and other stock owners filed with the SEC include: